QSAM Biosciences is a clinical‐stage biotechnology company specializing in the application of its proprietary Quantitative Structure–Activity Relationship (QSAR) platform to identify and optimize novel small molecules for cancer immunotherapy and precision oncology. The company’s core R&D capabilities combine in silico modeling with high‐throughput screening to accelerate lead identification and streamline preclinical development.
QSAM’s product pipeline encompasses both therapeutic and diagnostic programs. On the therapeutic side, the company is advancing preclinical candidates targeting solid tumors and hematologic malignancies, with a focus on immunomodulatory mechanisms. In parallel, its diagnostics division develops biomarker‐driven assays for early cancer detection and patient stratification, aiming to deliver point‐of‐care and laboratory‐based solutions that enhance clinical decision‐making.
Founded in 2013 and headquartered in Tirat Carmel, Israel, QSAM Biosciences maintains research facilities and strategic partnerships in the United States, Europe and Asia. The company collaborates with leading academic institutions and contract research organizations to extend its discovery efforts and out‐license select assets, accelerating the translation of its technologies into clinical settings.
QSAM’s leadership team is spearheaded by Chief Executive Officer Dr. David A. Brainard, a veteran of biopharmaceutical R&D and corporate strategy, alongside Chief Scientific Officer Dr. Lena Weiss, an expert in immuno‐oncology research. Supported by a board of advisors drawn from top cancer centers and precision medicine experts, QSAM remains committed to advancing innovative oncology solutions through scientific rigor and collaborative partnerships.
AI Generated. May Contain Errors.
